Recent Updates
Recently added Catalysts

somatropin

Phase 3

Growth Hormone Disorder | Small molecule | Endocrine |Novo Nordisk A/S|Last Updated: Feb 28, 2017

Success Probability
Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
Premium
Market & Valuation
rNPV $3.2B
Market Size $9.4B
Revenue Basis $1.6B
Competitors 6
Premium
Trial Design
RandomizedDouble-BlindACTIVE_CONTROLLEDBiomarker
Total Trials9
Total Enrollment1,134
FDA Designations
No designations recorded
Clinical Trials (9)
NCT IDTitlePhaseStatusEnrollmentVelocityDesignStartCompletionLast UpdatedSitesCountries
NCT00184730Long-term Trial on Growth Hormone Deficiency in Adults (GHDA)PHASE3 COMPLETED 86Nov 1, 2004Sep 1, 2006Nov 17, 20161 Japan
NCT00184743Long-term Trial on Growth Hormone Deficiency in Adults (GHDA)PHASE3 COMPLETED 112Dec 6, 2003Dec 28, 2005Feb 28, 20171 Japan
NCT00519558Growth Hormone Deficiency in Adults (GHDA)PHASE3 COMPLETED 121May 31, 2003Jan 24, 2005Feb 28, 20171 Japan
NCT00102817Somatropin (Norditropin) in Insulin-like Growth Factor (IGF) Deficient ChildrenPHASE3 COMPLETED 149May 1, 2003Dec 1, 2006Jan 18, 201727 United States
NCT00184678Effect of Growth Hormone on Bone Mineral Density in Young Adults With Child-hood Onset Growth Hormone DeficiencyPHASE3 COMPLETED 161Feb 1, 2002Jul 1, 2006Jan 13, 201730 Australia, Austria +10
NCT01502124Safety and Efficacy of Somatropin in Children With Growth Hormone DeficiencyPHASE3 COMPLETED 78May 8, 2001Mar 5, 2003Feb 28, 201721 United States
NCT01563926Evaluating Acceptance of New Liquid Somatropin Formulation in Children With Growth Hormone DeficiencyPHASE3 COMPLETED 168Oct 23, 2000Oct 10, 2002Feb 27, 20176 Israel
NCT00262249Effect of Growth Hormone in Children With Growth Hormone DeficiencyPHASE3 COMPLETED 173Aug 1, 2000May 1, 2004Jan 18, 201740 United States
NCT00931476A Single Dose Trial in Healthy Caucasians and Japanese Subjects Investigating the Pharmacokinetics of SomatropinPHASE1 COMPLETED 86Apr 6, 2000Jun 8, 2000Feb 27, 20171 United States
Unlock Drug Trial Details
Study Endpoints
Primary Endpoints
Lipid-related laboratory tests parameters (total cholesterol, HDL-cholesterol, LDL-cholesterol, and triglyceride)
at the end of treatment
GH-related laboratory parameters (IGF-I, IGF-I SDS, IGFBP-3, IGFBP-3 SDS and IGF-I / IGFBP-3 molar ratio)
at the end of treatment
Percent change in truncal fat (kg)
from the baseline to the end of treatment
Percent change in truncal fat (kg) from baseline
at 24 weeks (end of treatment)
Change in height standard deviation score
12 months
Changes in bone mineralisation
After 2 years treatment
Adverse events (especially injection site reactions)
Serious adverse events
Patient acceptance of the new liquid growth hormone formulation
Area under the hGH concentration-time curve (GH AUC0-24h)
from 0 to 24 hours following injection
Maximum hGH concentration (GH Cmax)
from 0 to 24 hours following injection
Treatment Emergent Adverse Events
from 0 to 24 hours following injection
Secondary Endpoints
Adverse events
FPG, insulin, and HbA1C
Clinical laboratory tests
Unlock Study Endpoints
Study Design & Arms
AllocationRANDOMIZED
MaskingNONE
ModelPARALLEL
PurposeTREATMENT
Treatment Arms
ArmTypeDescription
LyophilizedACTIVE_COMPARATOR -
LiquidEXPERIMENTAL -
SomatropinEXPERIMENTAL -
Interventions
NameTypeDescription
somatropinDRUG -
placeboDRUG -
Unlock Study Design Details
Eligibility Criteria
Age Range19 Years — 67 Years
SexALL
Healthy VolunteersNo
Study Sites1

Inclusion Criteria: * Subjects who completed GHLiquid-1519. * If the subject has a history of treatment for a tumor of pituitary or peripheral site, two years or more have to be passed since completion of surgery, radiotherapy or other treatment, and recurrence of the underlying disease to be exclu...

Countries:JapanUnited StatesAustraliaAustriaBelgiumFranceGermanyHungaryNorwayPolandSpainSwedenSwitzerlandUnited KingdomIsrael
Unlock Eligibility Criteria